Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Status and Forecast 2020-2026
SKU ID : QYR-15117653 | Publishing Date : 22-Jan-2020 | No. of pages : 99
Detailed TOC of Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Status and Forecast 2020-2026
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue
1.4 Market Analysis by Type
1.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Corticosteroid Therapy
1.4.3 IVIG Treatment
1.4.4 Plasma Exchange Therapy
1.4.5 Immunosuppressive Drug Therapy
1.4.6 Immunomodulator Therapy
1.4.7 Other
1.5 Market by Application
1.5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Specialist Neurology Clinic
1.5.4 Research and Academic Laboratories
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Perspective (2015-2026)
2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Trends by Regions
2.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Share by Regions (2015-2020)
2.2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Strategy
2.3.6 Primary Interviews with Key Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Market Size
3.1.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue (2015-2020)
3.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Players (2015-2020)
3.1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio
3.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2019
3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players Head office and Area Served
3.4 Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
3.5 Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Type (2015-2020)
4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2021-2026)
5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Application (2015-2026)
5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020)
6.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in North America (2019-2020)
6.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020)
6.4 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
7 Europe
7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020)
7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Europe (2019-2020)
7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020)
7.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
8 China
8.1 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020)
8.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in China (2019-2020)
8.3 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020)
8.4 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
9 Japan
9.1 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020)
9.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Japan (2019-2020)
9.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020)
9.4 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020)
10.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020)
10.4 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
11 India
11.1 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020)
11.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in India (2019-2020)
11.3 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020)
11.4 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020)
12.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Central & South America (2019-2020)
12.3 Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020)
12.4 Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Teijin Pharma
13.1.1 Teijin Pharma Company Details
13.1.2 Teijin Pharma Business Overview and Its Total Revenue
13.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.1.4 Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020))
13.1.5 Teijin Pharma Recent Development
13.2 Shire
13.2.1 Shire Company Details
13.2.2 Shire Business Overview and Its Total Revenue
13.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.2.4 Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.2.5 Shire Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview and Its Total Revenue
13.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.3.4 Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Octapharma
13.4.1 Octapharma Company Details
13.4.2 Octapharma Business Overview and Its Total Revenue
13.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.4.4 Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.4.5 Octapharma Recent Development
13.5 Momenta Pharmaceuticals
13.5.1 Momenta Pharmaceuticals Company Details
13.5.2 Momenta Pharmaceuticals Business Overview and Its Total Revenue
13.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.5.4 Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.5.5 Momenta Pharmaceuticals Recent Development
13.6 Mitsubishi Tanabe Pharma Corporation
13.6.1 Mitsubishi Tanabe Pharma Corporation Company Details
13.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview and Its Total Revenue
13.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.6.4 Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.6.5 Mitsubishi Tanabe Pharma Corporation Recent Development
13.7 Kedrion
13.7.1 Kedrion Company Details
13.7.2 Kedrion Business Overview and Its Total Revenue
13.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.7.4 Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.7.5 Kedrion Recent Development
13.8 Grifols
13.8.1 Grifols Company Details
13.8.2 Grifols Business Overview and Its Total Revenue
13.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.8.4 Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.8.5 Grifols Recent Development
13.9 CSL Behring (CSL Limited)
13.9.1 CSL Behring (CSL Limited) Company Details
13.9.2 CSL Behring (CSL Limited) Business Overview and Its Total Revenue
13.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.9.4 CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.9.5 CSL Behring (CSL Limited) Recent Development
13.10 Bio Products Laboratory
13.10.1 Bio Products Laboratory Company Details
13.10.2 Bio Products Laboratory Business Overview and Its Total Revenue
13.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
13.10.4 Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
13.10.5 Bio Products Laboratory Recent Development
13.11 Baxter
10.11.1 Baxter Company Details
10.11.2 Baxter Business Overview and Its Total Revenue
10.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
10.11.4 Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
10.11.5 Baxter Recent Development
13.12 MedDay Pharmaceuticals
10.12.1 MedDay Pharmaceuticals Company Details
10.12.2 MedDay Pharmaceuticals Business Overview and Its Total Revenue
10.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
10.12.4 MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
10.12.5 MedDay Pharmaceuticals Recent Development
13.13 GeNeuro Pharmaceuticals
10.13.1 GeNeuro Pharmaceuticals Company Details
10.13.2 GeNeuro Pharmaceuticals Business Overview and Its Total Revenue
10.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction
10.13.4 GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
10.13.5 GeNeuro Pharmaceuticals Recent Development
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Figures, Tables and Charts Available in Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Status and Forecast 2020-2026
List of TablesTable 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Market Segments
Table 2. Key Players Covered: Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue
Table 3. Ranking of Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Corticosteroid Therapy
Table 6. Key Players of IVIG Treatment
Table 7. Key Players of Plasma Exchange Therapy
Table 8. Key Players of Immunosuppressive Drug Therapy
Table 9. Key Players of Immunomodulator Therapy
Table 10. Key Players of Other
Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2015-2020)
Table 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Strategy
Table 21. Main Points Interviewed from Key Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players
Table 22. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Players (2015-2020) (Million US$)
Table 23. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players (2015-2020)
Table 24. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2019)
Table 25. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service
Table 28. Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 31. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Type (2015-2020)
Table 32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2021-2026)
Table 33. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Application (2015-2020)
Table 34. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 35. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Application (2021-2026)
Table 36. North America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020)
Table 38. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 39. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020)
Table 40. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 41. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020)
Table 42. Europe Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020)
Table 44. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020)
Table 46. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020)
Table 48. China Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$)
Table 49. China Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020)
Table 50. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 51. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020)
Table 52. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 53. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020)
Table 54. Japan Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020)
Table 56. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020)
Table 58. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020)
Table 62. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020)
Table 64. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020)
Table 66. India Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$)
Table 67. India Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020)
Table 68. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 69. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020)
Table 70. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 71. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020)
Table 74. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020)
Table 76. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020)
Table 78. Teijin Pharma Company Details
Table 79. Teijin Pharma Business Overview
Table 80. Teijin Pharma Product
Table 81. Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 82. Teijin Pharma Recent Development
Table 83. Shire Company Details
Table 84. Shire Business Overview
Table 85. Shire Product
Table 86. Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 87. Shire Recent Development
Table 88. Pfizer Company Details
Table 89. Pfizer Business Overview
Table 90. Pfizer Product
Table 91. Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 92. Pfizer Recent Development
Table 93. Octapharma Company Details
Table 94. Octapharma Business Overview
Table 95. Octapharma Product
Table 96. Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 97. Octapharma Recent Development
Table 98. Momenta Pharmaceuticals Company Details
Table 99. Momenta Pharmaceuticals Business Overview
Table 100. Momenta Pharmaceuticals Product
Table 101. Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 102. Momenta Pharmaceuticals Recent Development
Table 103. Mitsubishi Tanabe Pharma Corporation Company Details
Table 104. Mitsubishi Tanabe Pharma Corporation Business Overview
Table 105. Mitsubishi Tanabe Pharma Corporation Product
Table 106. Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 107. Mitsubishi Tanabe Pharma Corporation Recent Development
Table 108. Kedrion Company Details
Table 109. Kedrion Business Overview
Table 110. Kedrion Product
Table 111. Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 112. Kedrion Recent Development
Table 113. Grifols Business Overview
Table 114. Grifols Product
Table 115. Grifols Company Details
Table 116. Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 117. Grifols Recent Development
Table 118. CSL Behring (CSL Limited) Company Details
Table 119. CSL Behring (CSL Limited) Business Overview
Table 120. CSL Behring (CSL Limited) Product
Table 121. CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 122. CSL Behring (CSL Limited) Recent Development
Table 123. Bio Products Laboratory Company Details
Table 124. Bio Products Laboratory Business Overview
Table 125. Bio Products Laboratory Product
Table 126. Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 127. Bio Products Laboratory Recent Development
Table 128. Baxter Company Details
Table 129. Baxter Business Overview
Table 130. Baxter Product
Table 131. Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 132. Baxter Recent Development
Table 133. MedDay Pharmaceuticals Company Details
Table 134. MedDay Pharmaceuticals Business Overview
Table 135. MedDay Pharmaceuticals Product
Table 136. MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 137. MedDay Pharmaceuticals Recent Development
Table 138. GeNeuro Pharmaceuticals Company Details
Table 139. GeNeuro Pharmaceuticals Business Overview
Table 140. GeNeuro Pharmaceuticals Product
Table 141. GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$)
Table 142. GeNeuro Pharmaceuticals Recent Development
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type: 2020 VS 2026
Figure 2. Corticosteroid Therapy Features
Figure 3. IVIG Treatment Features
Figure 4. Plasma Exchange Therapy Features
Figure 5. Immunosuppressive Drug Therapy Features
Figure 6. Immunomodulator Therapy Features
Figure 7. Other Features
Figure 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2020 VS 2026
Figure 9. Hospital Case Studies
Figure 10. Specialist Neurology Clinic Case Studies
Figure 11. Research and Academic Laboratories Case Studies
Figure 12. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Years Considered
Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions: 2020 VS 2026
Figure 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players in 2019
Figure 18. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2019
Figure 20. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Teijin Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Teijin Pharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 29. Shire Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Shire Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 31. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Pfizer Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 33. Octapharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Octapharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 35. Momenta Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Momenta Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 37. Mitsubishi Tanabe Pharma Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Mitsubishi Tanabe Pharma Corporation Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 39. Kedrion Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Kedrion Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 41. Grifols Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Grifols Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 43. CSL Behring (CSL Limited) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. CSL Behring (CSL Limited) Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 45. Bio Products Laboratory Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Bio Products Laboratory Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 47. Baxter Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Baxter Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 49. MedDay Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. MedDay Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 51. GeNeuro Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. GeNeuro Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Keyplayers in Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Status and Forecast 2020-2026
Teijin PharmaShire
Pfizer
Octapharma
Momenta Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Kedrion
Grifols
CSL Behring (CSL Limited)
Bio Products Laboratory
Baxter
MedDay Pharmaceuticals
GeNeuro Pharmaceuticals